MENU
CLLS
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

Cellectis SA (CLLS) Ownership - Who owns Cellectis SA?

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications... Show more

Industry: #Biotechnology

Profile

Industry
Biotechnology
Address
8, rue de la Croix Jarry
Phone
+33 181691600
Employees
285
Web
https://www.cellectis.com

Details

Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
280.74M
P/E Ratio
N/A
Total Cash
196.15M
Projected Growth
N/A
Total Debt
94.77M
Revenue
56.3M
Risk (Beta)
3.85
Dividend Yield
N/A
Total Cash/Share
1.96
Total Debt/Equity
N/A
Revenue/Share
0.56 USD as % of share price

Fundamentals

CLLS
Capitalization
281M
P/E Ratio
N/A
Risk (Beta)
3.85
Dividend Yield
N/A
Total Cash
196M
Total Cash/Share
1.96
Total Debt
94.8M
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0.56%
Revenue
56.3M
ROE
N/A
Book Value
97.1M
P/B Ratio
2.76
Cash Flow
N/A
Earnings
-0.59
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
5.9M
Current Ratio
1.38
Current Revenue Per Employee
75337.84
Dividends Per Share - Security
N/A
EBITDA
-30.25M
Float
N/A
Float - Current
N/A
Gross Income Margin
85.50
Revenue To Assets
-15.50
Shares Held By Institutions
20M
Shares Outstanding - Current
100M
Total Liabilities
257M
Total Volume MTD
N/A
Value
1
Gain YTD
48.333
View a ticker or compare two or three
CLLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. CLLS showed earnings on August 04, 2025. You can read more about the earnings report here.
A.I. Advisor
published General Information

General Information

a genome engineering company of pre-engineered products for pharmaceutical industry, cell therapies, seed companies, and laboratory researchers

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
8, rue de la Croix Jarry
Phone
+33 181691600
Employees
285
Web
https://www.cellectis.com